Crucell corporate brochure (PDF)

Our business – Products
areas as well as visitors to these regions. Outbreaks of severe disease
in regions where cholera is endemic put local populations at risk
of serious illness and death. Travelers’ diarrhea caused by cholera is
generally not life-threatening but is distressing and debilitating, spoiling
many holidays and business trips. This preventable diarrheal infection
is now the most common travel illness but remains an under-recognized
problem. Dukoral® was first licensed in 1992 and is now registered in
65 countries for the prevention of cholera, with additional indications
(ETEC, travelers’ diarrhea) in some of these countries. It is an oral
inactivated vaccine approved for use in adults and children from
two years of age. Dukoral® drinkable vaccine is easy to use and offers
84–86% protection against cholera, as demonstrated in field clinical
trials on various continents. Dukoral® also has a reassuringly favorable
safety profile, with an adverse event rate comparable to placebo
reported in clinical trials. The vaccine’s safety and tolerability has
been confirmed over many years of use around the world.
Inflexal® V
Inflexal® V virosomal adjuvanted vaccine offers protection against
influenza thanks to its virosome technology—one of Crucell’s patented
innovations. Virosomes are reconstituted influenza virus envelopes,
constructed without the genetic information of the virus so that they
are unable to replicate or cause infections. In the context of vaccines,
virosomes serve as both a carrier system and an adjuvant.
Inflexal® V is the only adjuvanted influenza vaccine licensed for all
age groups (from 6 months upwards).
Since its launch in 1997, Inflexal® V has been licensed in 38 countries
with over 60 million doses distributed. Extensive experience in
the market has confirmed its efficacy and favorable safety profile.
The vaccine’s unique design and manufacturing process eliminate the
need for thiomersal (a vaccine preservative) or formaldehyde (commonly
used to inactivate influenza viruses) and minimize residual traces of
antibiotics, detergent and hen’s egg protein compared with other
influenza vaccines.
The vaccine’s antigen composition changes in accordance with annual
recommendations issued by the World Health Organization (WHO)
on the basis of data on the circulating influenza virus strains.
Other products
We also distribute a variety of other products, such as Gardasil®
(Merck) and Prolastin® (Talecris).
31